How do you lead amidst change?
New Science: A new reality for biopharma growth | Accenture
Biopharma: Changing the economic relationship with customers
New Science The new economics in biopharma
New Science: Billions to millions
What if you could find opportunities to tie profitability to improvements in patients’ health, rewarding the innovation and better outcomes from New Science?
1. New Science is more important than ever
New Science is projected to drive 81% of biopharma revenue growth and 61% of all revenues between 2021 and 2026, outpacing our previous forecast of 54% of all revenues from 2017-2022.
expected higher average net present value (NPV) for New Science treatments versus traditional counterparts from 2022-2026.
of all new deals intended to create new therapies in the last 5 years involved New Science treatments.
2. A new economic reality challenges profitability
3. Success requires a future-fit enterprise to address both sides of the profitability equation
Addressing the profitability equation
Meet the team
Managing Director – Asia Pacific Life Sciences Lead
Managing Director – Accenture Strategy, Commercial, Sales and Marketing, Life Sciences
Visit our Subscription and Preference Center